Triaditis — concurrent pancreatitis, inflammatory bowel disease, and cholangiohepatitis — is common in middle-aged cats. Welfare management of this complex condition requires systematic, coordinated treatment.
Triaditis represents one of the most complex welfare management challenges in feline medicine. The concurrent disease state means that signs from one condition may mask improvement in another, treatment for one organ system may exacerbate another, and the overall welfare burden exceeds the sum of any single disease. Cats with triaditis are often significantly unwell, showing profound inappetence, weight loss, jaundice, and systemic malaise that reflects the combined inflammatory burden.
Nutritional support is a welfare-critical priority in triaditis management. Cats that stop eating are at risk of hepatic lipidosis, which compounds existing liver disease. Early enteral nutrition — via nasogastric or esophagostomy tube — maintains hepatic function and accelerates recovery. Palatable, easily digestible food that addresses both the gastrointestinal and hepatic components of triaditis is essential.
Managing triaditis requires coordinated treatment of all three conditions: prednisolone for IBD and cholangiohepatitis, ursodeoxycholic acid for hepatic support, anti-nausea medication, antibiotics for secondary bacterial cholangiohepatitis, and nutritional support. Regular monitoring of liver enzymes, pancreatic lipase, and clinical signs guides treatment adjustment over the often prolonged management course.